While many cases of focal segmental glomerulosclerosis have no known cause, doctors have identified possible causes for a type of this disorder known as secondary focal segmental glomerulosclerosis.

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Long-term abuse of anabolic steroids can lead to focal segmental glomerulosclerosis (FSGS), according to a recent study. Although anabolic steroid abuse is known to have adverse effects on the ...

Travere Therapeutics (TVTX) announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration and plans to ...

Buy FSGS near 29.44 target 30.82 stop loss @ 29.35 Details; The technical summary data tells us to buy FSGS near 29.44 with an upside target of ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...